C L Fortner
Overview
Explore the profile of C L Fortner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
ODwyer P, King S, Fortner C, Leyland-Jones B
J Clin Oncol
. 1986 Aug;
4(8):1262-9.
PMID: 3525769
An analysis of hypersensitivity reactions to teniposide was approached using three methods: investigator survey, adverse drug reaction analysis, and literature search. By the survey method, hypersensitivity incidence was 6.5% with...
2.
ODwyer P, Donehower M, Sigman L, Fortner C, Aisner J, Van Echo D
J Clin Oncol
. 1985 Jun;
3(6):853-7.
PMID: 4009219
N-methylformamide (NMF) is a polar-planar solvent with both cytotoxic and differentiating activity in preclinical models; it also acts as a radiosensitizer. We treated 17 patients with 18 courses of NMF...
3.
Finley R, Fortner C, Grove W
Drug Intell Clin Pharm
. 1985 May;
19(5):362-7.
PMID: 3891281
Nephrotoxicity is usually the dose-limiting toxicity associated with cisplatin therapy. Frequently the nephrotoxicity is mild and reversible. However, it is both dose-related and cumulative and may become life-threatening and irreversible...
4.
Fortner C, Finley R, Grove W
Drug Intell Clin Pharm
. 1985 Jan;
19(1):21-4.
PMID: 3967569
Severe nausea and vomiting are frequent complications of cancer chemotherapy. Historically, single-agent antiemetic therapy frequently has been less than optimal. Because multiple sites of emetogenic activity may be involved in...
5.
Danhauer F, Fortner C, Schimpff S, deJongh C, Wesley M, Wiernik P
Clin Pharm
. 1982 Nov;
1(6):539-43.
PMID: 7185540
Pharmacokinetic principles were used to determine amikacin doses for granulocytopenic cancer patients on empirical antibiotic regimens, and audiometry was used to determine the effect of this treatment on auditory acuity....
6.
Fortner C, Finley R, Schimpff S
Pharmacotherapy
. 1982 Nov;
2(6):287-99.
PMID: 6220262
Piperacillin sodium is a beta lactam antibiotic with a broad range of antibacterial activity that includes gram-negative bacilli, gram-positive cocci (except penicillinase-producing S. aureus) and anaerobic pathogens such as Clostridium...
7.
Finley R, Fortner C, deJongh C, Wade J, Newman K, Caplan E, et al.
Antimicrob Agents Chemother
. 1982 Aug;
22(2):193-7.
PMID: 6765414
The capabilities of two pharmacokinetic amikacin dosing methods were evaluated and compared with the standard amikacin dosage recommended by the manufacturer. Study patients participated in two consecutive prospective randomized double-blind...
8.
Finley R, Schimpff S, Fortner C, Wiernik P
Clin Pharm
. 1982 Jul;
1(4):370-2.
PMID: 7185534
No abstract available.
9.
Grove W, Fortner C, Wiernik P
Clin Pharm
. 1982 Jul;
1(4):320-6.
PMID: 6764391
The pharmacology, chemistry, pharmacokinetics, clinical studies, and adverse effects of amsacrine, an investigational antineoplastic agent, are reviewed. Amsacrine's mechanism of action is not clearly understood, although the drug is known...
10.
de Jongh C, Wade J, Schimpff S, Newman K, Finley R, Salvatore P, et al.
Am J Med
. 1982 Jul;
73(1):89-96.
PMID: 6211981
Moxalactam is a new cephalosporin with a broad spectrum of activity which includes Pseudomonas aeruginosa in addition to Klebsiella species Escherichia coli, and Staphylococcus aureus. Moxalactam was combined with amikacin...